© 2014 Medidata Solutions, Inc. Can Big Data/Real World Data Cure Life Science’s R&D Malaise? Glen de Vries Founder and President.

Slides:

Advertisements

Similar presentations

Personalized Medicine in California Kathryn Lowell, Deputy Secretary for Life Sciences and Health Systems February, 2009.

Advertisements

ESRC Stem Cell Initiative: Capacity Building and Awareness Raising. 1st Annual Meeting. 30th November 2006.

Eli Lilly and Company – Tailored Therapeutics and Diagnostics © Eli Lilly and Company 2012 The views and opinions expressed herein and/or during the accompanying.

Care Transitions: Technology Panel Panelists: Marcus Grindstaff, Vice President, US Sales And Global Market Development Intel-GE Care Innovations Matt.

Prize4Life: Inducement Prizes for ALS (Lou Gehrig’s Disease) Nicole Szlezak Member, Board of Directors Prize4Life.

11 Express Scripts Dan Winkler & Stephanie Zimmermann October 6, 2014 Group 10.

Philip J. Ditchfield Manager, Contracts & Licensing GlaxoSmithKline Data Mining and the Pharmaceutical Industry.

Health Care Costs: Issues for Business Economic Summit & Outlook 2006 presented by CBIA and MetroHartford Alliance Thursday, January 5, 2006 The Connecticut.

Oncological Sciences Center Mission: To rapidly translate research findings to the clinic by engaging clinical partners in the discovery process Vision:

Innovation and Efficiency in clinical research solutions Clinical Trial solutions Luca Emili – CEO

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Oracle Health Sciences Global Business Unit Strategy Steve Rosenberg Senior Vice.

Leveraging Patient Engagement & the Role of Advocacy.

Biomedical Research to Translational Medicine Saigal A. MS *, Tuteja D. PhD and Chaturvedi D. PhD Bio Business Inc., 400 Continental Blvd, 6th Floor, El.

Building a Roadmap for Research IT John Brussolo Research IT Program Director September 6, 2012 © 2012 The Regents of the University of Michigan.

Welcome Rebecca Wood Chief Executive. Welcome Alzheimer’s Research UK.

Global Leadership in Medical Innovation: “Ours to Lose”

Engineering the future: universities and education Sir Keith O’Nions President & Rector June 2014.

Robert J. Matheis, PhD, MA Executive Director, Global Scientific Communications Celgene Corp. Integrating Communication/Publication Strategy as Part of.

Collaborative Team Science to Advance New Therapies for Epilepsy “The CURE Infantile Spasms and Epilepsy Genetics Initiatives”

Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,

The Innovative Medicines Initiative (IMI) High level the IMI Concept, Strategic Research Agenda and Call topics Eva Lindgren.

A Systems Approach: BIG Health Consortium™ “The world we have created today has problems which cannot be solved by thinking the way we thought when we.

Anticipated FY2016 Appropriations Agency$ Million NIH200 Cancer70 Cohort130 FDA10 Office of the Natl Coord. for Health IT (ONC) 5 TOTAL215 Mission: To.

Barriers to innovation – and solutions The Collaboration Conundrum Colette Goldrick, Director ABPI Northern Ireland.

Confidential Hovione © Highlighting projects for Erlangen: Synergies Finder Route 1 – Pro-Active Approach -Identify intra-Innostar competencies.

September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.

HTA cooperation in the EU EPF workshop Jérôme Boehm 18 May 2010.

AIFA European Conference on Clinical Research for Decision Making Sergio Dompé - Farmindustria Rome, March 30th, 2007 Access to market by new medicines.

“Life Sciences in an Oil City” World-Class Research.

The Innovative Medicines Initiative A winning case for Joint Technology Initiative Status.

PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.

Adaptive Licensing UK. Content What is adaptive licensing? Draft criteria for pilot candidate selection EMA Road Map 2015 and work programme 2012 UK perspective.

By Georgi Boyanov BUS 449a: Change Management.  Statistics  History  Medicinal recipes  Vaccines  Innovation  Mergers & Acquisitions.

PRESENTATION TITLE | DATE Moving the Life Science Industry Forward.

Reducing bottlenecks: Rare-purposing™ Action Duchenne, November 07, 2015 David Cavalla, CSO, Healx.

Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.

1 Clinical Champion Quarterly Learning Session Dec 11, 2015 Agenda  CTC strategies and initiatives and request for feedback  Review of OHIC standards.

The Solution: Foundation for Patient Powered Solutions Deploy a shared enterprise solution that will empower patient advocacy organizations to share in.

Digital Inclusion for Inclusive growth Laveesh Bhandari IAMAI, Mumbai, September 9, 2014.

Aligning Policy Agendas The case of personalised care and cure for healthy and active ageing Setting the scene for the DG Regio and Flanders Smart Specialisation.

How Laws are Made. House, Senate, President 1 21 st Century Cures Legislation: Modernizing Drug Development in Pursuit of Cures Stephen Smith Chief Patient.

BIG DATA Initiative SMART SubstationBig Data Solution.

Clinical Trial Management System Market forecast to reach $2.4bn by 2024

“Let’s Do This…. No, Let’s Do That”

9/10/2018 Largest US Healthcare Dataset in Hadoop enables Patient-level Analytics in Near Real Time September 28, 2016 Navdeep Alam Director of Data.

An introduction to personalised medicine & health in Leeds

Parasites have clocks iMM-Lisboa Should FCT fund discovery research,

Biography Assistant Vice Chancellor for Commercial Translation in the Health Sciences Visiting Associate Professor, Department of Biomedical Informatics.

Scientific Excellence Innovation Collaboration

EU funding opportunities

<Company Name & Logo>

Executive Structure – 1 September 2012

Innovation, HealthEd and Universal Health Coverage : Where next?

Finland, a Global Testbed for Personalized Cancer Research?

The National Academies of Sciences, Engineering, and Medicine

New Targets, New Modalities, New Challenges – The Inconvenient Path of Human Genetics in Drug Discovery Enabling Precision Medicine: The Role of Genetics.

Omar M. Lattouf, MD, PhD, FACC, FACS

Cardiovascular Diseases Faculty of Medicine Second Annual Retreat

A new approach to delivery

The Big 6 Research Model Step 2: Information Seeking Strategies

Innovative Medicines Initiative:

Implantable Medical Devices: Accelerating Standards Development to Streamline Regulation Joshua Price | August 2,

Digital Health Landscape in Malaysia

Croatia, Zagreb, June 29, 2018 Ljiljana Sović Brkičić

Troy Schneider Sarah Halek

Gwyn Tudor Forum Manager - MediWales

OUR HISTORY & MISSION ABOUT US. OUR HISTORY & MISSION ABOUT US.

Ukrainian Cluster in Health and Wellness sector

Stratified Medicine: Will it be the Future of Medicine?

Vylyny Chat, Robert Ferguson, Tomas Kirchhoff

Presentation transcript:

© 2014 Medidata Solutions, Inc. Can Big Data/Real World Data Cure Life Science’s R&D Malaise? Glen de Vries Founder and President

DevelopmentCommercial RegulatorsPayers Efficacy Data Effectiveness Data © 2014 Medidata Solutions, Inc.

DevelopmentCommercial RegulatorsPayers The Same Data © 2014 Medidata Solutions, Inc.

*omics Clinical mHealth © 2014 Medidata Solutions, Inc.

MEDIDATA, AN INTRODUCTION

6

ENGAGE, COLLABORATE, INNOVATE

The GADGET Method Development Effort + © 2014 Medidata Solutions, Inc.

Genetic Biomarkers Phenotypic Biomarkers Digital Biomarkers © 2014 Medidata Solutions, Inc.

12

13

The Medidata MOVE-2014 Study © 2014 Medidata Solutions, Inc.

SafetyPrivacyRegulation Objections © 2014 Medidata Solutions, Inc.

ApprovalPatent Expiration Value (Therapeutic & Economic) Time Baseline Value Commercial Patient Engagement Strategy Clinical Development Patient Engagement Strategy lost annually from patients not taking their medicines £350 Billion Therapeutic Benefits! + © 2014 Medidata Solutions, Inc.

There will be life sciences companies using objectively measured digital biomarker data with both regulators and payers… And there will still be life sciences companies that are not 2020 Predictions © 2014 Medidata Solutions, Inc.

10 years from now life sciences companies that don’t use digital biomarkers as part of their solutions will no longer exist © 2014 Medidata Solutions, Inc.

Thank you!